Home > Oncology > SABCS 2019 > Long-Term Study Results > Anastrozole yields long term effects in the prevention of breast cancer occurrence

Anastrozole yields long term effects in the prevention of breast cancer occurrence

Conference
SABCS 2019
Trial
IBIS-II

The updated analysis of the IBIS-II trial showed that breast cancer incidence among postmenopausal women who are at high risk of developing the disease continued to be significantly reduced 5.9 years after stopping a 5-year treatment period with the aromatase inhibitor (AI) anastrozole. These results indicate a long-term preventive benefit with anastrozole for oestrogen receptor (ER)-positive breast cancer in postmenopausal women.

IBIS-II Prevention was designed to investigate whether 5 years of anastrozole can safely and effectively prevent breast cancer in postmenopausal women who are at high risk for developing the disease [1]. This was the case if these women fulfilled any one of a number of criteria, such as having 2 or more blood relatives with breast cancer, having a mother or sister who developed breast cancer at an age <50, or having a mother or sister who had breast cancer in both breasts. The primary objective of this study was to determine the effic...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on